Identification of a New Metabolite of Furosemide in Humans

Completed

• Conditions: Treatment by Furosemide

• Registration Number: NCT02872168
• Lead Sponsor: Henri Mondor University Hospital

Brief Summary

Recent in-vitro and in-vivo studies performed by one of the investigators (ESO, ICMPE, UPEC, France) have recently allowed to synthetize a new and easy-to-synthesized chemical compound of the furosemide (pyridinium furosemide) during furosemide degradation by electro-Fenton or bioconversion. The biological properties of pyridinium furosemide are currently under investigation. Furosemide is a diuretics currently used in the treatment of patients with heart failure. The goal of the investigators is to assay pyridinium furosemide in urine of patients treated by furosemide to demonstrate that pyridinium is or not a metabolite of furosemide in humans. This study will contribute to assess the fate of pharmaceutical residues of furosemide in the environment.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-06
• Primary Completion: 2016-02
• Study Completion: 2016-02
• Status Verified: 2016-08
• Study First Submitted: 2016-08-16
• Study First Submitted QC: 2016-08-18
• Last Update Submitted: 2016-08-18
• Study First Posted: 2016-08-19
• Last Update Posted: 2016-08-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age ≥ 18 years
2. Written informed consent
3. Affiliation to social security
4. Known heart failure
5. Treatment by furosemide

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assay of furosemide and pyridinium furosemide in urine of heart failure patients treated by furosemide	1 day	Assay of furosemide and pyridinium furosemide in urine of heart failure patients treated by furosemide